HIGHLIGHTS
- who: PARP and colleagues from the Central South University, China have published the article: Olaparib and advanced ovarian cancer: Summary of the past and looking into the future, in the Journal: (JOURNAL)
- what: The authors provided an overview of the clinical and pre-clinical characteristics of olaparib, synthesizing the results of trials that led to its approval in different settings and analyzing its safety profile.
- how: The combination of olaparib and the anti-PD-L1 durvalumab was tested in two ongoing phase II trials reporting strong response rates. The authors declare that the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.